OncoMatch/Clinical Trials/NCT06577311
Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis)
Is NCT06577311 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Aminolevulinic acid hydrochloride 10% topical gel with Red Light for cutaneous squamous cell carcinoma.
Treatment: Aminolevulinic acid hydrochloride 10% topical gel with Red Light — The goal of this clinical trial is to test how safe and effective it is to treat early form of cancer cells found in the upper skin layer of the face, using a light-sensitive gel used in combination with a light source. The main questions this trial aims to answer are: * to confirm using laboratory testing, how much of the affected facial skin cancer section the treatment was able to remove, and; * seeing how many participants had no remaining affected facial skin cancer sections after treatment. Participants who qualify will be asked to complete 14 visits in total and will receive a total of two treatments, after voluntarily consent has been given.
Check if I qualifyEligibility summary
For patients with Cutaneous Squamous Cell Carcinoma.
This summary was generated by AI from the trial's official eligibility criteria and may contain errors. Always confirm with the study team before contacting a site.
US trial sites
- Center for Clinical and Cosmetic Research · Aventura, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify